• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ARYA Sciences Acquisition Corp IV

    2/14/24 7:36:44 AM ET
    $ARYD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARYD alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934*

     

    ARYA SCIENCES ACQUISITION CORP. IV

    (Name of Issuer)

     

    Class A Ordinary Share, $0.0001 par value

    (Title of Class of Securities)

     

    G31659108

    (CUSIP Number)

     

    April 10, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. G31659108

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Tenor Capital Management Company, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, USA

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    300,000*

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    300,000*

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    300,000*

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.2%*

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA

     

     
     

     

    CUSIP No. G31659108

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Tenor Opportunity Master Fund, Ltd.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    300,000*

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    300,000*

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    300,000*

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.2%*

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

     
     

     

    CUSIP No. G31659108

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Robin Shah

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    300,000*

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    300,000*

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    300,000*

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.2%*

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN, HC

     

     
     

     

    CUSIP No. G31659108

     

    Item 1. (a). Name of Issuer:
         
        Arya Sciences Acquisition Corp. IV
         
      (b). Address of issuer’s principal executive offices:
         
       

    51 Astor Place, 10th Floor,

    New York, NY 10003

         
         
    Item 2. (a). Name of person filing:
         
       

    Tenor Capital Management Company, L.P.*

    Tenor Opportunity Master Fund, Ltd.*

    Robin Shah*

         
         
        Address or principal business office or, if none, residence:
         
      (b). Tenor Capital Management Company, L.P.
        Tenor Opportunity Master Fund, Ltd.
        Robin Shah
         
        810 Seventh Avenue, Suite 1905, New York, NY 10019
         
         
       (c). Citizenship:
         
        Tenor Capital Management Company, L.P. – Delaware, USA
       

    Tenor Opportunity Master Fund, Ltd. – Cayman Islands

    Robin Shah – USA

     

         
       (d) Title of class of securities:
         
        Class A Ordinary Share, $0.0001 par value
         
        CUSIP No.:
         
      (e). G31659108

     

     
     

     

    CUSIP No. G31659108

     

    Item 3. If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a)   ☐   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
               
      (b)   ☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
               
      (c)   ☐   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
               
      (d)   ☐   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-
              8).
      (e)   ☐   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
               
      (f)   ☐   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
               
      (g)   ☐   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
               
      (h)   ☐   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
               
      (i)   ☐   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
               
      (j)   ☐   A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
               
      (k)   ☐   Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     
     

     

    CUSIP No. G31659108

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:

     

    Tenor Capital Management Company, L.P. – 300,000 *

    Tenor Opportunity Master Fund, Ltd. – 300,000 *

    Robin Shah – 300,000 *

     

     

      (b) Percent of class:

     

    Tenor Capital Management Company, L.P. – 7.2%*

    Tenor Opportunity Master Fund, Ltd. – 7.2%*

    Robin Shah – 7.2%*

     

     

      (c) Number of shares as to which Tenor Capital Management Company, L.P. has:

     

      (i) Sole power to vote or to direct the vote   0 ,
               
      (ii) Shared power to vote or to direct the vote   300,000* ,
               
      (iii) Sole power to dispose or to direct the disposition of   0 ,
               
      (iv) Shared power to dispose or to direct the disposition of   300,000* .
               
      Number of shares as to which Tenor Opportunity Master Fund, Ltd. has:      
               
      (i) Sole power to vote or to direct the vote   0 ,
               
      (ii) Shared power to vote or to direct the vote   300,000* ,
               
      (iii) Sole power to dispose or to direct the disposition of   0 ,
               
      (iv) Shared power to dispose or to direct the disposition of   300,000* .

     

      Number of shares as to which Robin Shah has:      
               
      (i) Sole power to vote or to direct the vote   0 ,
               
      (ii) Shared power to vote or to direct the vote   300,000* ,
               
      (iii) Sole power to dispose or to direct the disposition of   0 ,
               
      (iv) Shared power to dispose or to direct the disposition of   300,000* .

     

    *The Class A Ordinary Share, $0.0001 par value, (the “Shares”) of Arya Sciences Acquisition Corp. IV (the “Issuer”) are reported herein.

     

    The Shares reported herein are held by Tenor Opportunity Master Fund, Ltd. (the “Master Fund”). Tenor Capital Management Company, L.P. (“Tenor Capital”) serves as the investment manager to the Master Fund. Robin Shah serves as the managing member of Tenor Management GP, LLC, the general partner of Tenor Capital.

     

    By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the Shares owned directly by the Master Fund. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the Shares for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of the Reporting Person’s pecuniary interest therein.

     

    The percentages herein are calculated based upon a statement in the Issuer’s Form 10-Q, filed on November 9, 2023 indicating that there are 4,189,831 Shares issued and outstanding.

     

     
     

     

    CUSIP No. G31659108

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

    N/A

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

    N/A

     

     
     

     

    CUSIP No. G31659108

     

    Item 8. Identification and Classification of Members of the Group.

     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d- 1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

     

    N/A

     

    Item 9. Notice of Dissolution of Group.

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

    N/A

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     
     

     

    CUSIP No. G31659108

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024 Tenor Capital Management Company, L.P.
       
      By: /s/ Robin Shah
      Name: Robin Shah
      Title: Managing Member of its general partner, Tenor Management GP, LLC

     

      Tenor Opportunity Master Fund, Ltd.
       
      By: /s/ Robin Shah
      Name: Robin Shah
      Title: Authorized Signatory

     

      Robin Shah
       
      By: /s/ Robin Shah
      Name: Robin Shah

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     

     

    CUSIP No. G31659108 Exhibit 1

     

    Joint Filing Statement

     

    Statement Pursuant to Rule 13d-1(k)(1)

     

    The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Shares, each consisting of one share of Class A Ordinary Share, $0.0001 par value of Arya Sciences Acquisition Corp. IV, beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties hereto further consent and agree to file this Statement pursuant to Rule 13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G.

     

    Dated: February 14, 2024    
         
      Tenor Capital Management Company, L.P.
       
      By: /s/ Robin Shah
      Name: Robin Shah
      Title:

    Managing Member of its general partner, Tenor

    Management GP, LLC

     

      Tenor Opportunity Master Fund, Ltd.
       
      By: /s/ Robin Shah
      Name: Robin Shah
      Title: Authorized Signatory

     

      Robin Shah
       
      By: /s/ Robin Shah
      Name: Robin Shah

     

     

     

    Get the next $ARYD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARYD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ARYD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adagio Medical Provides Business Updates

      Adagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company"))), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. Recent Business Highlights: Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal Obtained the U.S. Food and Drug Administration ("FDA") approval for the FULCRUM-VT Pivotal IDE study Cl

      8/19/24 4:01:00 PM ET
      $ADGM
      $ARYD
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Adagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of Cardiac Arrhythmias

      Business combination transaction with ARYA Sciences Acquisition Corp IV, a special purpose acquisition company sponsored by an affiliate of Perceptive Advisors, closed on July 31, 2024 Publicly traded company renamed Adagio Medical Holdings, Inc., with Adagio Medical as an operating subsidiary Common stock expected to commence trading under ticker symbol "ADGM" on the Nasdaq Capital Market on August 1, 2024 Adagio Medical, Inc. ("Adagio Medical"), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, announced today the completion of its business combination with ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD, or "ARYA IV"))), a special purpos

      7/31/24 4:01:00 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

      MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

      5/6/24 6:25:00 AM ET
      $ARYD
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARYD
    Financials

    Live finance-specific insights

    See more
    • Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: "Caritas Therapeutics"

      Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding Will Transform Amicus into a Premier Global Commercialization and Late Stage Product Development Biotechnology Company in Rare Diseases Transaction Advances Amicus Path to Profitability - Expected as of 2023 Amicus Balance Sheet Further Strengthened with a ~$200M Private Investment from Leading Biotechnology Investors Separation will Sharpen the Strategic Focus, Financial Profile, and Operational Execution of Both Companies to Address the Needs of People Living with Rare Diseases – A

      9/29/21 6:30:00 AM ET
      $ARYD
      $FOLD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ARYD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Stone Adam Leo returned 499,000 units of Class A ordinary shares to the company (SEC Form 4)

      4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)

      7/31/24 9:52:23 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Henderson Michael Thomas

      4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)

      7/31/24 9:49:31 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Trigg Leslie

      4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)

      7/31/24 9:46:16 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARYD
    Leadership Updates

    Live Leadership Updates

    See more

    $ARYD
    SEC Filings

    See more
    • Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

      MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

      5/6/24 6:25:00 AM ET
      $ARYD
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 15-12G filed by ARYA Sciences Acquisition Corp IV

      15-12G - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)

      8/12/24 4:30:11 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 25-NSE filed by ARYA Sciences Acquisition Corp IV

      25-NSE - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)

      7/31/24 5:16:44 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ARYA Sciences Acquisition Corp IV filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)

      7/26/24 4:30:22 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARYD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ARYA Sciences Acquisition Corp IV

      SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)

      6/28/24 5:09:55 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by ARYA Sciences Acquisition Corp IV (Amendment)

      SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)

      5/10/24 4:31:19 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by ARYA Sciences Acquisition Corp IV

      SC 13G - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)

      2/14/24 3:30:36 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care